• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西沙必利对进行性系统性硬化症患者结肠转运的影响。

Effects of cisapride on colonic transit in patients with progressive systemic sclerosis.

作者信息

Wang S-J, Lan J-L, Lan J-L, Chen D-Y, Chen Y-H, Hsieh T-Y, Lin W-Y

机构信息

Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

出版信息

Clin Rheumatol. 2002 Aug;21(4):271-4. doi: 10.1007/s100670200072.

DOI:10.1007/s100670200072
PMID:12189451
Abstract

Progressive systemic sclerosis (PSS) may involve any portion of the gastrointestinal tract, including the colon. Constipation is common in patients with PSS. Cisapride, a benzamide derivative, is a potentially useful agent in the treatment of chronic idiopathic constipation. The effect of cisapride on colonic transit was evaluated in 16 PSS patients by a radionuclide colonic transit method. Each patient received cisapride orally three times a day for a week. The results showed acceleration in colonic transit in response to cisapride. We conclude that cisapride is effective in the treatment of constipation in patients with PSS.

摘要

进行性系统性硬化症(PSS)可能累及胃肠道的任何部分,包括结肠。便秘在PSS患者中很常见。西沙必利是一种苯甲酰胺衍生物,是治疗慢性特发性便秘的一种潜在有效药物。通过放射性核素结肠运输法对16例PSS患者评估了西沙必利对结肠运输的影响。每位患者每天口服西沙必利三次,共一周。结果显示,西沙必利可使结肠运输加速。我们得出结论,西沙必利对治疗PSS患者的便秘有效。

相似文献

1
Effects of cisapride on colonic transit in patients with progressive systemic sclerosis.西沙必利对进行性系统性硬化症患者结肠转运的影响。
Clin Rheumatol. 2002 Aug;21(4):271-4. doi: 10.1007/s100670200072.
2
Cisapride accelerates colonic transit in constipated patients with colonic inertia.西沙必利可加速患有结肠惰性的便秘患者的结肠转运。
Am J Gastroenterol. 1989 Aug;84(8):882-7.
3
Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis.西沙必利对进行性系统性硬化症患者固体食物食管转运的影响。
Clin Rheumatol. 2002 Feb;21(1):43-5. doi: 10.1007/s100670200010.
4
[Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].[多种促动力药物对进行性系统性硬化症患者胃肠道转运时间的影响]
Z Gastroenterol. 1997 Oct;35(10):905-12.
5
The effect of cisapride on segmental colonic transit time in patients with spinal cord injury.西沙必利对脊髓损伤患者节段性结肠转运时间的影响。
Am J Gastroenterol. 1995 Feb;90(2):285-9.
6
Anorectal dysfunction and delayed colonic transit in patients with progressive systemic sclerosis.进行性系统性硬化症患者的肛门直肠功能障碍和结肠传输延迟
Dig Dis Sci. 1993 Aug;38(8):1525-9. doi: 10.1007/BF01308615.
7
The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson's disease.西沙必利对特发性帕金森病患者结肠传输延迟时间的影响。
Wien Klin Wochenschr. 1994;106(21):673-6.
8
Cisapride accelerates colonic transit in constipated patients with colonic inertia.西沙必利可加速患有结肠惰性的便秘患者的结肠转运。
Am J Gastroenterol. 1990 Feb;85(2):216-7.
9
Radionuclide colon transit study in patients with idiopathic constipation.特发性便秘患者的放射性核素结肠运输研究
Hepatogastroenterology. 2002 Sep-Oct;49(47):1262-4.
10
Cisapride for the treatment of constipation in children: A double-blind study.西沙必利治疗儿童便秘:一项双盲研究。
J Pediatr. 2000 Jan;136(1):35-40. doi: 10.1016/s0022-3476(00)90046-5.

引用本文的文献

1
The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review.促动力药在硬皮病胃肠道受累管理中的作用:一项系统文献综述
Rheumatology (Oxford). 2025 Jun 1;64(6):3266-3279. doi: 10.1093/rheumatology/keaf064.
2
Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach.系统性硬化症胃肠道表现的管理:一种基于机制的方法。
Expert Rev Clin Immunol. 2024 Jun;20(6):603-622. doi: 10.1080/1744666X.2024.2320205. Epub 2024 Feb 26.
3
A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.
系统性硬化症患者胃肠道症状评估与管理的实用方法。
Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101666. doi: 10.1016/j.berh.2021.101666. Epub 2021 Mar 4.
4
Intestinal Involvement in Systemic Sclerosis: A Clinical Review.系统性硬化症的肠道累及:临床综述。
Dig Dis Sci. 2018 Apr;63(4):834-844. doi: 10.1007/s10620-018-4977-8. Epub 2018 Feb 21.
5
Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.系统性硬化症胃肠道临床试验的考虑要点。
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v4-v11. doi: 10.1093/rheumatology/kex195.
6
Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.普芦卡必利治疗系统性硬化症(SSc)相关肠道病变的初步安全性和疗效概况:开放标签交叉PROGASS研究结果
Arthritis Res Ther. 2017 Jun 20;19(1):145. doi: 10.1186/s13075-017-1340-y.
7
Gastrointestinal Manifestations of Systemic Sclerosis.系统性硬化症的胃肠道表现
J Scleroderma Relat Disord. 2016;1(3):247-256. doi: 10.5301/jsrd.5000214. Epub 2016 Oct 18.
8
Anorectal motility and sensation abnormalities and its correlation with anorectal symptoms in patients with systemic sclerosis: a preliminary study.系统性硬化症患者的肛门直肠动力和感觉异常及其与肛门直肠症状的相关性:一项初步研究。
ISRN Gastroenterol. 2011;2011:402583. doi: 10.5402/2011/402583. Epub 2011 Jun 6.
9
Profile of gastrointestinal involvement in patients with systemic sclerosis.系统性硬化症患者的胃肠道受累特征。
Rheumatol Int. 2012 Aug;32(8):2471-8. doi: 10.1007/s00296-011-1988-6. Epub 2011 Jul 19.
10
Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma.系统性硬化症患者的胃肠道症状和动力障碍
BMC Gastroenterol. 2008 Feb 27;8:7. doi: 10.1186/1471-230X-8-7.